First, More Vectors. Then, More Genes
This month's merger agreement between financially sound, but scientifically narrow Cell Genesys Inc. (Foster City, CA)and the troubled, but technology-rich Somatix Therapy Corp. (Alameda, CA) [See Deal] was played to the investment community as an ideal match-up-a play for critical mass in the complex and clinically demanding field of gene therapy. Although the merits of size may seem self-evident, we may still ask, why is bigger better?
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.